MedTrace Logo

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

NCT06319950 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 255

Last updated 2024-03-20

No results posted yet for this study

Summary

The investigators were to explore whether high-dose Furmonertinib, compared with osimertinib, could achieve longer survival in patients with EGFR-mutated NSCLC with CNS metastasis.

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

DRUG

Furmonertinib

Furmonertinib, 160mg po qd

DRUG

Osimertinib

Osimertinib，80mg po qd

Sponsors & Collaborators

  • Taizhou Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-01
Primary Completion
2026-12-30
Completion
2026-12-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06319950 on ClinicalTrials.gov